# Day 2 — Reviewer-Agent Claim Gate Review

**Project:** PYRIN-PLAQUE Digital Twin
**Gate:** Day 2 Claim Gate (literature evidence graph + novelty audit)
**Date:** 2026-07-07
**Reviewer:** adversarial reviewer agent (Claude Science `host.llm`) — audits only; creates no new claims.

## Inputs audited
- 57 atomic claims across axes A–E (evidence/claim_cards.md, manifests/evidence_table.tsv, evidence/evidence_graph.jsonl).
- Sources verified via real connector calls: PubMed (search + metadata + ID conversion), ClinicalTrials.gov (trial details), InterPro/protein-annotation (MEFV domains). bioRxiv attempted (keyword search unsupported by connector; PubMed used as primary — logged).

## Claim counts by axis
- A (pyrin-specific): 12
- B (NLRP3-general atherosclerosis): 11
- C (shared downstream pyroptosis): 9
- D (clinical alignment): 15
- E (method precedent / novelty risk): 10
- **Total: 57**  (target 40–60; each major axis ≥8; E ≥8 — met)

## Eight-point claim gate

**1. Does every claim have a real resolvable source?**
PASS — All 57 claims carry a resolvable id (PMID / DOI / NCT / InterPro). 0 claims without a source. All literature PMIDs were validated against the fetched PubMed corpus (0 invalid).

**2. Is each claim actually supported by the cited source?**
PASS (with process caveat) — Claims were extracted directly from fetched abstracts with source-grounding instructions; the reviewer re-checked each for over-reach. High-impact anchor claims (A1–A5) map to the correct papers. Manual PI spot-check of the 10 strongest pyrin claims recommended before Day 3 (standard human-in-loop checkpoint).

**3. Are pyrin-specific / NLRP3-general / shared-downstream claims separated correctly?**
PASS — Axis A is restricted to pyrin-specific regulatory biology (RhoA/PKN/14-3-3/PSTPIP1/MEFV) + InterPro domain evidence; axis B is NLRP3/atherosclerosis; shared downstream effectors carry shared_downstream_flag on 28 claims total across all axes (A:1, B:10, C:9, D:8) — including all 9 axis-C claims — and are NOT used as discriminative pyrin-vs-NLRP3 evidence (enforces Day-1 caveat 1).

**4. Are clinical trial claims framed only as clinical alignment?**
PASS — CANTOS (NCT01327846, n=10066), COLCOT (NCT02551094, n=4745), LoDoCo2 (NCT03048825, n=7264) are all recorded as clinical-alignment evidence. Each carries an explicit caveat that the benefit does NOT prove a pyrin-specific mechanism (colchicine/IL-1 action is not pyrin-exclusive).

**5. Are any "firstness" or causal claims present?**
PASS — 0 FAIL-level claims. No firstness language; no "MEFV causes atherosclerosis"; no "expression proves causality". Two FMF-cardiovascular claims (C-D-09, C-D-10) initially risked reading as causal; the gate downgraded C-D-10 confidence and reworded C-D-09 to explicit association-only framing.

**6. Are any anchor papers misrepresented?**
PASS — All 5 anchors resolved to correct PMIDs/DOIs and are represented per their actual content: A1 (HIV/atherosclerosis inflammation), A2 (galectin-3→NLRP3 pyroptosis), A3 (HDAC3→endothelial NLRP3), A4 (integrated plaque single-cell atlas — cited as method precedent, NOT used as a data source), A5 (residual inflammatory risk / vulnerable plaque).

**7. Is the final novelty claim conservative and defensible?**
PASS — The novelty statement (evidence/novelty_audit.md) explicitly acknowledges that NLRP3-in-atherosclerosis, integrated plaque atlases, and single-cell+bulk+MR+druggability pipelines are already common (6 atherosclerosis papers in our sample combine ≥3 such methods), and frames the contribution as the pyrin-specific, cell-state-resolved, auditable integration. No "first ever".

**8. Which claims should be removed or downgraded before Day 3?**
- **Downgraded:** C-D-10 (FMF remission cytokines) — confidence lowered; correlative, not mechanistic.
- **Reworded:** C-D-09 (FMF premature atherosclerosis) — association-only caveat added; not causal.
- **No removals required.** No claim reached FAIL.

## Gate result
- Reviewer status tally: {'PASS': 56, 'FLAG': 1}
- **Verdict: PROCEED_WITH_CAVEATS.** The evidence graph is source-grounded, pyrin/NLRP3-separated, and the novelty framing is conservative. Recommended human checkpoint before Day 3: PI spot-check of the top-10 pyrin-specific claims.

## Carry-forward constraints (unchanged from Day 1 + new)
1. Shared downstream genes remain non-discriminative (Day-1 caveat 1) — honored in evidence graph.
2. DS_SC_ATLAS_INTEGRATED stays NEEDS_REVIEW; anchor A4 is a literature precedent only, not a data source.
3. Clinical-alignment claims may never be used as mechanistic proof of pyrin involvement.
